SHANGHAI, CHINA, and PRINCETON, N. J., USA – Media OutReach – 12 May 2023 – LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, announced yesterday that CAMZYOS ^®(mavacamten) has received marketing approval for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) from the Pharmaceutical Administration Bureau of the Macau SAR.

“Hypertrophic cardiomyopathy is a cardiovascular disease that significantly impacts the quality of life of patients,” said Dr. Xiuhua Feng, Consultant of Cardiology at Kiang Wu Hospital. “We are very pleased to see the approval of mavacamten in Macau, as it will bring hope to local patients living with this chronic and debilitating condition.”

“Macau marks mavacamten’s first approval in LianBio’s licensed territories,” said Yizhe Wang, Ph.D., Chief Executive Officer of LianBio. “This approval is a major milestone for patients in the region and demonstrates LianBio’s commitment to accelerating patient access throughout Asia to innovative new treatments.”

In April 2023, the China National Medical Products Administration (NMPA) accepted with Priority Review the New Drug Application for mavacamten for the treatment of adults with symptomatic oHCM.

In April 2023, LianBio announced positive topline results from the Phase 3 EXPLORER-CN trial investigating mavacamten for the treatment of Chinese patients with symptomatic oHCM. EXPLORER-CN met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in Valsalva left ventricular outflow tract (LVOT) gradient from baseline to week 30 compared to placebo (p<0.001). Additionally, mavacamten demonstrated clinically important improvements for all secondary endpoints, including change from baseline to week 30 in resting LVOT peak gradient, proportion of participants achieving a Valsalva LVOT peak gradient <30 mmHg at week 30, proportion of participants achieving a Valsalva LVOT peak gradient <50 mmHg at week 30, proportion of participants with at least one NYHA class improvement from baseline to week 30, change from baseline to week 30 in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS), and change from baseline to week 30 in left ventricular mass index evaluated by cardiac magnetic resonance imaging. Safety results in the trial were consistent with previous studies of mavacamten in symptomatic oHCM, and no new safety signals were reported.

Hashtag: #LianBio #CAMZYOS

The issuer is solely responsible for the content of this announcement.

About Mavacamten

CAMZYOS (mavacamten) is the first and only cardiac myosin inhibitor approved by the U.S. FDA indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III oHCM to improve functional capacity and symptoms. It has also received regulatory approvals in Australia, Canada, Brazil, Switzerland and Macau. CAMZYOS is an allosteric and reversible inhibitor selective for cardiac myosin. CAMZYOS modulates the number of myosin heads that can enter “on actin” (power generating) states, thus reducing the probability of force producing (systolic) and residual (diastolic) cross-bridge formation. Excess myosin actin cross bridge formation and dysregulation of the super relaxed state are mechanistic hallmarks of HCM. CAMZYOS shifts the overall myosin population towards an energy sparing, recruitable, super relaxed state. In HCM patients, myosin inhibition with CAMZYOS reduces dynamic left ventricular outflow tract (LVOT) obstruction and improves cardiac filling pressures.

LianBio licensed rights from MyoKardia, now a wholly owned subsidiary of Bristol Myers Squibb, in August 2020 for the development and commercialization of mavacamten in Mainland China, Hong Kong, Macau, Taiwan, Thailand and Singapore. Mavacamten was granted Breakthrough Therapy Designation in China for the treatment of patients with oHCM in February 2022.

About Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is a chronic, progressive disease in which excessive contraction of the heart muscle and reduced ability of the left ventricle to fill can lead to the development of debilitating symptoms and cardiac dysfunction. HCM is estimated to affect one in every 500 people globally. The most frequent cause of HCM is mutations in the heart muscle proteins of the sarcomere. In both obstructive and non-obstructive HCM patients, exertion can result in fatigue or shortness of breath, interfering with a patient’s ability to participate in activities of daily living. HCM has also been associated with increased risks of atrial fibrillation, stroke, heart failure and sudden cardiac death.

In China, there are an estimated 1.1 million to 2.8 million patients with HCM.

About LianBio

LianBio is a cross-border biotechnology company on a mission to bring transformative medicines to historically underserved patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, and inflammatory disease. LianBio is establishing an international infrastructure to position the company as a partner of choice with a platform to provide access to China and other Asian markets. For more information, please visit www.lianbio.com.

Ramping up on their decarbonisation efforts, the steel manufacturer seeks to enhance the competitiveness of Indonesia’s steel industry on the global stage.

JAKARTA, INDONESIA – Media OutReach – 12 May 2023 – PT Gunung Raja Paksi Tbk (GRP), a member of the Gunung Steel Group, is further championing Indonesia’s sustainability agenda by kickstarting a value chain ecosystem for the nation’s steel sector. With an aim to enhance the competitiveness of Indonesia’s steel industry while advancing sustainability goals, a Focus Group Discussion (FGD) was recently held with key members of the Ministry of Industry, Ministry of Trade, the Net Zero Hub of the Indonesia Chamber of Commerce (KADIN), the World Resources Institute, PT Tata Metal Lestari (Tatalogam Group) as well as the University of Indonesia among other partners.

The preliminary FGD initiates an important conversation for the heavy-weight industry and GRP aims to achieve the following:

• Explore potential collaborations and partnerships with a shared vision and mission to achieve decarbonisation and greenhouse gas (GHG) emission reductions.

• Lead the formation of a green industry-based ecosystem that promotes sustainability and raise awareness to support the government’s targets for achieving Nationally Determined Contribution (NDC) and Net Zero in 2060, with a realistic and measurable roadmap and work plan.

• Improve the competitiveness of the national steel industry by adopting sustainability principles and optimising the Indonesian Green Industry Standard, which would be recognised by all international green standards, and encourage competitive export activities.

• Emerge as a leading community and centre of excellence for green industry by delivering world-class, environmentally friendly steel products and total solutions with transparent environmental disclosures, to consumers and investors worldwide.

The collaboration and information sharing between industry players is critical to reducing GHG emissions on a global scale as every product is linked to different industry players, and emissions are produced at each stage of the value chain. Steel manufacturing is a prime example of the key value chain as steel is a core building material that is traded between countries. The global steel industry is one of the drivers of pollution globally, contributing up to 4.1% of the world’s total CO2 emissions and about 3.2% of all GHG emissions. ^[1] With more than 70% of global steel production operating in Asia, the industry must innovate to reduce direct and indirect fuel consumption and CO2 emissions^[2]. An ambitious, long-term plan for the industry is crucial to achieving decarbonisation targets and reducing emissions.

“Decarbonisation and sustainability are ambitious goals that no single company can achieve alone. It requires the collaboration of every stakeholder across the value chain. Today’s supply chains are more interconnected than ever. To achieve a more sustainable ecosystem, we need to align our goals and action plans in reducing GHG emissions. The recent FGD is a crucial step in bringing together diverse stakeholders and understanding their perspectives towards sustainability. By working together, we are determined to set Indonesia’s steel industry as a standard for sustainability which can inspire other countries to follow suit. We are determined to lead this effort and look forward to working closely with like-minded industry players to build a cleaner future,” said Kimin Tanoto, Member of the Executive Committee at GRP.

The Indonesian government has also articulated its plans towards sustainability and earlier this year, the country has reaffirmed its commitment to achieving its Enhanced Nationally Determined Contribution (ENDC) to reduce its emissions by approximately 31.9% unconditionally and achieve Net Zero emissions by 2060 or sooner. This is a goal which GRP and its partners are committed to supporting.

“Together with GRP, we have initiated the conversation around establishing a green ecosystem via the forum as a commitment between both steel companies to speed up and enhance the target of achieving net zero by 2060. GRP is our strategic supplier, and through our efforts we have supplied customers in over 16 countries, with sustainably produced steel, while staying compliant to the sustainability standards of each country” said Stephanus Koeswandi, Vice President, PT Tata Metal Lestari.

Following its recent sustainability initiatives, which include developing an ESG Strategy Handbook and reiterating their commitment to reducing GHG emissions via the Net Zero Roadmap, GRP envisions a future where low carbon steel will become a core building material in every infrastructure. As part of its ESG strategy, GRP has been working closely with suppliers in its supply chain to ensure compliance and alignment on ESG criteria and standards. GRP’s Net Zero Roadmap outlines concrete steps towards decarbonisation, including fuel switching, green power sourcing, and carbon offsetting.

Hashtag: #GunungRajaPaksi #ShapingTomorrow #Sustainability

The issuer is solely responsible for the content of this announcement.

About GRP

PT Gunung Raja Paksi Tbk (GRP) is part of the Gunung Steel Group, which is one of Indonesia’s major private steel businesses. Our company began its operations in 1970 in Medan, North Sumatra, by producing hot steel, then progressed to manufacture steel beams and sheets.

With over 50 years of steel industry experience, GRP has a production capacity of 2,200,000 tons of high-quality steel annually approved by local and international certifying company.

Today, our company has become one of the largest private steel companies in Indonesia. Gunung Raja Paksi, “Shaping Tomorrow”. Together we develop a better future.

For more information, please visit: www.gunungrajapaksi.com